Myoviridae LL12.
The fourth bacteriophage strain in the PreforPro blend, targeting harmful gut bacteria. Expands the PreforPro blend's target range by going after a different set of harmful gut bacteria than the other three phages.
Reviewed March 2026
- Category
- General
- Also filed under
- Broadens bacterial targeting spectrum in PreforProSupports microbiome balancePart of studied phage cocktail
What Myoviridae LL12 is, and what it does.
- Does it work
- It suits people who want gut support working alongside probiotics rather than adding another live culture. It comes as one of four phages, taken as the blend.
- How much to take
- 15 mg as part of the PreforPro blend. There's no way to dose LL12 individually, and no reason to try.
- Time to feel it
- Nothing acute. In the four-phage blend it belongs to, gut bacterial and comfort measures shifted over about four weeks of daily use.
- The first dose
- Nothing perceptible. The phage is doing its microscopic work, but you won't notice.
- With regular use
- Weeks 3-4: potential mild improvements in digestive comfort as part of the full blend's effects.
- How well tolerated
- Well tolerated. Like all bacteriophages, LL12 can only infect specific bacteria. Human cells are completely off-limits.
- How it feels
- You can't feel individual phages. The blend as a whole may produce subtle improvements in gut comfort over time.
- The overlooked benefit
- Phages are choosy. LL12 only lands on bacteria carrying the receptor it binds, so the lactobacilli and bifidobacteria you're feeding are not on its list.
15mg a day is where Myoviridae LL12 works.
Source: Gindin et al., 2019 (PreforPro blend study)
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
- Reduces harmful gut bacteria populations
- Multi-phage approach prevents resistance
Questions people ask about Myoviridae LL12.
- Why do you need four phages instead of one?
- Each phage only targets specific bacteria. One phage alone is too narrow. Four phages cover more ground and make it harder for bacteria to develop resistance. It's like sending four different specialists instead of one.
- What happens if the phages run out of targets?
- They naturally decline. Phages can only replicate inside their target bacteria. No targets, no replication, phages get cleared. It's a beautifully self-regulating system.
- Can I take this with antibiotics?
- Yes, but there's a catch. Antibiotics might kill the bacteria that phages need to replicate. It won't harm you, but the phages become less effective during antibiotic treatment.
- Is this well tolerated in kids?
- Based on the mechanism, yes. Phages can't interact with human cells regardless of age. But PreforPro hasn't been specifically studied in children, so talk to your pediatrician.
- How is this different from a probiotic?
- Probiotics add good bacteria. Phages remove bad bacteria. They're complementary strategies. Taking both is actually smarter than either alone.
- Will I need to take this forever?
- Not necessarily. If your gut ecosystem stabilizes, you might not need ongoing supplementation. But if the harmful bacteria return (diet, stress, antibiotics), you might benefit from another round.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Phage host specificity is settled microbiology and cuts both ways. A Myoviridae preparation aimed at gram-negative targets should not lyse a Lactobacillus or Bifidobacterium strain. Whether a given commercial phage overlaps a given probiotic strain is a product-level question the label has to answer.
The two occupy different sides of the same niche, one reducing a target population and one adding a resident. The complementarity depends entirely on the phage cocktail's declared host range. Read it as a formulation rationale, not a measured combination effect.
Host specificity is why a phage preparation and a bifidobacterial supplement are formulated together. The claim is about who the phage can infect, not about a measured shift in either population when both are taken.
This is settled virology. A phage preparation cannot act on Saccharomyces boulardii in either direction. The pairing is mechanically independent, which is the whole point of combining them.
Inulin's fermentation by bifidobacteria is established. A phage cocktail selectively reduces a susceptible host population. Formulas combine subtraction and feeding, and the combined effect on community composition has not been measured in the sources available here.
The fibre feeds residents while the phage acts on a specific host. Neither depends on the other chemically. The rationale is community-level and unquantified here.
Fermentation substrate and phage lysis act on different levers of the same community. The combination is a formulation choice. No study of the pair is cited here.
Supplying butyrate directly is nutritional support of the colonic epithelium. A phage preparation acts on bacteria and not on the host cell. The two are mechanically independent.
Phage capsids and tail structures lose infectivity under strong acid, which is why oral phage products use acid protection. A betaine hydrochloride supplement pushes gastric pH down. Taking the two at the same time works against the phage preparation's survival to the intestine.
Raising gastric pH is the mechanism behind antacid co-administration in phage delivery work. Whether an over-the-counter bicarbonate dose does this reliably in a fed stomach is unstated here. Read it as a plausible delivery aid rather than a measured one.
A phage virion is a protein and nucleic acid particle, exactly the size class charcoal adsorbs. Co-administration would be expected to reduce the number of active virions reaching the colon. Separating the two by several hours is the conventional handling of any charcoal interaction.
Clay adsorbents bind virions non-specifically. Taking one with a phage preparation is expected to lower the delivered active count. This is mechanistic reasoning, not a measured loss.
Supplemental protease exposure is a plausible route to capsid damage, though phage capsids are comparatively protease resistant and intestinal proteases are already present. The concern is mechanistic and unquantified. Separating doses is the cautious handling.
Nothing about glutamine metabolism touches phage infectivity or bacterial host receptors. The two sit in the same formula addressing different targets. Independence here is the useful fact.
Host-directed and microbe-directed ingredients do not compete mechanically. The pairing is a formulation choice in gut-support blends. No combination measurement is cited here.
Immunoglobulin binding and phage adsorption both target bacterial surface molecules, so some receptor competition is conceivable. It has not been measured in the sources here. The direction of any net effect is unknown and should be stated as such.
Talk to a doctor before taking Myoviridae LL12 if any of these apply to you: Individual strain effects unknown, Part of a blend, not studied alone. These are flags to check first, not effects Myoviridae LL12 is known to cause.
Not medical advice. Show the label to your pharmacist.What Myoviridae LL12 actually does.
Bacteriophages are viruses that infect bacteria and only bacteria. They carry no receptors for human cells and don't replicate in your tissue.
Myoviridae is a shape-based grouping: icosahedral head, contractile tail. Members of this group are characteristically lytic, meaning they burst the host rather than settling in as a quiet passenger.
A lytic phage docks onto one specific surface receptor on its host bacterium, injects its genome, replicates and splits the cell open. That receptor fussiness is what keeps phage activity narrow instead of broad.
Bacteria get around a single phage through receptor changes, restriction-modification systems and CRISPR immunity. That's why phage preparations are built as cocktails of several phages aimed at different receptors.
Where Myoviridae LL12 comes from.
The phages are grown by letting them infect a tank of their target bacteria, the bacterial debris is filtered out, the remaining virus particles are counted, and the result is freeze dried into a stable powder.
Produced by a cultured organism rather than harvested. The strain is selected and the conditions are controlled, so batches sit closer together than a field crop.
A defined, characterised bacterial host strain is grown in a sterile fermentation medium to a target density.
The seed phage stock is added to the host culture at a set multiplicity of infection and allowed to replicate until the culture lyses.
Cell debris is removed by centrifugation, then the lysate is passed through sterilising-grade filters that retain bacteria while allowing virions through. Tangential flow filtration or density gradient steps concentrate the virions and remove host endotoxin.
Plaque assay establishes the plaque-forming unit count per millilitre, and individual phages are blended to a declared cocktail composition.
The blend is freeze dried with a cryoprotectant to a stable powder for capsule or blend use.
Which specific host strain a given commercial preparation is propagated on, and the identity of the phages in the cocktail, are usually held as proprietary and are not on the label.
Getting Myoviridae LL12 from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- In a 4-week randomised, double-blind, placebo-controlled trial in 68 healthy adults, adding a bacteriophage blend containing LL12 to a Bifidobacterium animalis subsp. lactis probiotic showed a within-group improvement in a self-reported gut symptom score (p = 0.01) and a larger rise in Lactobacillus and short-chain fatty acid producing bacteria than the probiotic alone.Randomised trial. Grubb et al., 2020 (Nutrients). PMID 32824480 ↗
These are the studies our verdict leans on, chosen from the 8 we read for Myoviridae LL12. The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.
